Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) has completed its inspection of Unit-2, an API manufacturing facility of its wholly owned subsidiary, Apitoria Pharma Private Limited. The facility, located at Gaddapotharam Village, Jinnaram Mandal, Sangareddy District, Telangana, was inspected from September 23 to September 27, 2024.
Following the inspection, the facility received an Establishment Inspection Report (EIR), classifying it as “Voluntary Action Indicated” (VAI). This classification signifies that the facility operates within regulatory compliance and that no critical issues were identified during the inspection.
The VAI status underscores Aurobindo Pharma’s commitment to maintaining high-quality manufacturing standards and regulatory compliance. This positive development further strengthens the company’s position in the global pharmaceutical market, ensuring the uninterrupted supply of Active Pharmaceutical Ingredients (APIs).
In the meantime, Aurobindo Pharma’s stock opened at ₹1,175.10, reaching a high of ₹1,175.45 and a low of ₹1,147.35. The stock has seen a 52-week high of ₹1,592.00 and a 52-week low of ₹958.50, reflecting fluctuations in its performance over the past year. As of 10 AM, the shares were trading 1.43% lower at Rs 1,159.45.
